DK0935469T3 - Anvendelse af væksthormon - Google Patents

Anvendelse af væksthormon

Info

Publication number
DK0935469T3
DK0935469T3 DK97919856T DK97919856T DK0935469T3 DK 0935469 T3 DK0935469 T3 DK 0935469T3 DK 97919856 T DK97919856 T DK 97919856T DK 97919856 T DK97919856 T DK 97919856T DK 0935469 T3 DK0935469 T3 DK 0935469T3
Authority
DK
Denmark
Prior art keywords
growth hormone
medicament
treatment
individuals
metabolic
Prior art date
Application number
DK97919856T
Other languages
Danish (da)
English (en)
Inventor
Per Marin
Lars Loenn
Malin Ottosson
Kaj Stenlof
Per Bjoerntorp
Lars Sjoestroem
Bengt-Ake Bengtsson
Gudmundur Johannsson
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Application granted granted Critical
Publication of DK0935469T3 publication Critical patent/DK0935469T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)
  • Steroid Compounds (AREA)
DK97919856T 1996-04-12 1997-04-10 Anvendelse af væksthormon DK0935469T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9601397A SE9601397D0 (sv) 1996-04-12 1996-04-12 Use of growth hormone
PCT/SE1997/000601 WO1997038709A1 (en) 1996-04-12 1997-04-10 Use of growth hormone

Publications (1)

Publication Number Publication Date
DK0935469T3 true DK0935469T3 (da) 2003-03-17

Family

ID=20402176

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97919856T DK0935469T3 (da) 1996-04-12 1997-04-10 Anvendelse af væksthormon

Country Status (11)

Country Link
EP (1) EP0935469B1 (de)
JP (1) JP2000510451A (de)
AT (1) ATE228007T1 (de)
CA (1) CA2250907A1 (de)
DE (1) DE69717301T2 (de)
DK (1) DK0935469T3 (de)
ES (1) ES2187771T3 (de)
NZ (1) NZ332105A (de)
PT (1) PT935469E (de)
SE (1) SE9601397D0 (de)
WO (1) WO1997038709A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087090A (en) * 1997-02-25 2000-07-11 Celtrix Pharmaceuticals, Inc. Methods for predicting drug response
CA2294824A1 (en) * 1997-07-04 1999-01-14 Pharmacia & Upjohn Ab Use of growth hormone in compositions for treating insulin resistance in the heart and for enhancing protein kinase b (pkb) activity
AU761880B2 (en) * 1998-11-26 2003-06-12 Auckland Uniservices Limited Treatment of hypertension
TW514510B (en) * 1999-06-11 2002-12-21 Tanita Seisakusho Kk Method and apparatus for measuring distribution of body fat
ATE381343T1 (de) * 1999-11-03 2008-01-15 Novo Nordisk As Verwendung eines wachstumshormons oder eines wachstumshormon-sekretion fördernden mittels zur appetit-unterdrückung bzw. sättigungsinduktion
SE0000837D0 (sv) 2000-03-13 2000-03-13 Pharmacia & Upjohn Ab New use
AU2006200127B2 (en) * 2000-03-13 2007-10-25 Pfizer Inc. Use of growth hormone in low dose
DE60140285D1 (de) 2000-05-31 2009-12-10 Pfizer Prod Inc Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
WO2003004068A1 (en) * 2001-07-06 2003-01-16 Auckland Uniservices Limited Hypertension treatment
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2005020898A2 (en) 2003-08-21 2005-03-10 Tercica, Inc. Methods of reducing visceral fat by increasing levels of insulin-like growth factor-i (igf-i)
WO2007059372A2 (en) * 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
CN101657436A (zh) 2007-02-09 2010-02-24 特兰齐姆制药公司 大环生长素释放肽受体调节剂及其使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268277A (en) * 1987-08-07 1993-12-07 Eniricerche S.P.A. Method for the preparation of human growth hormone

Also Published As

Publication number Publication date
NZ332105A (en) 2000-03-27
ATE228007T1 (de) 2002-12-15
DE69717301D1 (de) 2003-01-02
EP0935469A1 (de) 1999-08-18
EP0935469B1 (de) 2002-11-20
DE69717301T2 (de) 2003-09-04
PT935469E (pt) 2003-03-31
WO1997038709A1 (en) 1997-10-23
JP2000510451A (ja) 2000-08-15
CA2250907A1 (en) 1997-10-23
SE9601397D0 (sv) 1996-04-12
ES2187771T3 (es) 2003-06-16

Similar Documents

Publication Publication Date Title
DK0935469T3 (da) Anvendelse af væksthormon
Poirier et al. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients
Blair et al. Sustained compression and healing of chronic venous ulcers.
DE69809558D1 (de) Auswahlmethode für potentielle mittel gegen fettleibigkeit, zur regulierung des ucp-2
UA83854C2 (uk) Застосування телмісартану для підвищення чутливості до інсуліну
EP0766966A3 (de) Methode zur Behandlung der Insulinresistenz
US7169121B2 (en) Elastic dynamic immobilizer for fingers or toes
McGregor The free radial forearm flap—the management of the secondary defect
SE9201573D0 (sv) Use of igf-1
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
ATE290863T1 (de) Verwendung von prolactinmodulatoren und diät zur herstellung eines medikamentes zur behandlung der fettleibigkeit
WO2002070546A3 (en) Modified derivatives of cck-8
Ampudia-Blasco et al. A new case of lipoatrophy with lispro insulin in insulin pump therapy: is there any insulin preparation free of complications?
FR2836336B1 (fr) Utilisation dans un traitement cosmetique d'une fraction phenolique riche en dihydrochalcones
RU96115219A (ru) Способ лечения больных сахарным диабетом
ES2181923T3 (es) 4-hidroxicumarin-3-carboxamidas para el tratamiento de la diabet es mellitus no dependiente de la insulina.
DK0785787T3 (da) Anvendelse af 1,5-benzodiazepinderivater til kontrol af mavetømning hos patienter med ikke insulinafhængig diabetes mellitus
Gupta et al. Volar compartment syndrome of the arm complicating a fracture of the humeral shaft: A case report
EA200600757A1 (ru) Тетрапептид, регулирующий уровень глюкозы в крови при сахарном диабете
ES2168772T3 (es) Uso de hormona del crecimiento en composiciones para el tratamiento de la resistencia del corazon a la insulina.
Nerlich et al. The Iconodiagnosis of Johann Friedrich I. von Sachsen (1503–1554)’s Facial Wound and Cause of Death
BR0309375A (pt) Tratamento de sìndrome metabólica
Griera et al. D33 Effect of doxazosin on insulin-resistance in non-obese mild-to-moderate hypertensive patients
Holst et al. Diurnal profile of pancreatic polypeptide and gut glucagon in human morbid obesity
Lima Jr et al. D35 Placebo effects in hypertensive urgency